Lantern Pharma Inc. (LTRN)

Lantern Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	21.94	37.74	52.52	19.23	1.23
Short-Term Investments	19.36	17.99	19.2	0	0
Cash & Cash Equivalents	41.3	55.74	71.73	19.23	1.23
Cash Growth	-25.90%	-22.29%	273.00%	1460.78%	176.76%
Other Current Assets	2.04	2.99	0.99	1.01	0
Total Current Assets	43.34	58.72	72.72	20.24	1.23
Property, Plant & Equipment	0.28	0.1	0.22	0.02	0.01
Other Long-Term Assets	0.03	0.02	1.02	0.1	0.19
Total Long-Term Assets	0.31	0.11	1.23	0.12	0.2
Total Assets	43.65	58.84	73.95	20.36	1.43
Accounts Payable	2.51	2.75	2.17	0.55	0.49
Current Debt	0.17	0.05	0.15	0	0
Total Current Liabilities	2.68	2.8	2.33	0.55	0.49
Long-Term Debt	0.06	0	0.05	0.11	0
Total Long-Term Liabilities	0.06	0	0.05	0.11	0
Total Liabilities	2.74	2.8	2.38	0.66	0.49
Total Debt	0.23	0.05	0.2	0.11	0
Debt Growth	343.32%	-74.19%	88.89%	-	-
Retained Earnings	-55.24	-39.28	-25.02	-12.66	-6.75
Comprehensive Income	-0.11	-0.37	-0.09	0	0
Shareholders' Equity	40.91	56.04	71.57	19.7	0.94
Net Cash / Debt	41.07	55.68	71.52	19.12	1.23
Net Cash / Debt Growth	-26.25%	-22.14%	274.05%	1451.97%	176.76%
Net Cash Per Share	3.79	5.13	6.56	4.44	0.62
Working Capital	40.66	55.92	70.39	19.68	0.74
Book Value Per Share	3.77	5.17	6.56	4.58	0.48

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).